ConductScience.org, home

Paper9747868

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Fisher B and 14 others. J Natl Cancer Inst, 1998. Cited by 4,153 papers, by iCite.

Cite this record

ConductScience Library. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Papers, record 9747868. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9747868

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
PubMed
Journal
J Natl Cancer Inst
PubMed
Year
1998
PubMed
Publication types
Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
4,153
iCite
Relative citation ratio, by iCite
108
iCite
Revised in PubMed
2024-12-19
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fisher BB
2Costantino JPJ P
3Wickerham DLD L
4Redmond CKC K
5Kavanah MM
6Cronin WMW M
7Vogel VV
8Robidoux AA
9Dimitrov NN
10Atkins JJ
11Daly MM
12Wieand SS
13Tan-Chiu EE
14Ford LL
15Wolmark NN

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, HormonalMajor topic
Breast NeoplasmsMajor topic
Estrogen AntagonistsMajor topic
TamoxifenMajor topic
Adult
Cause of Death
Female
Humans
Middle Aged
Neoplasm Invasiveness
Odds Ratio
Quality of Life
Risk
Risk Factors
Treatment Outcome

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
U10-CA-37377NCI NIH HHSUnited StatesU10CA037377PubMed and NIHNIH RePORTER
U10-CA-69974NCI NIH HHSUnited StatesU10CA069974PubMed and NIHNIH RePORTER

Download CSV of grants

Trials7

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00001837Effects of Raloxifene on the Uterus and Ovaries of Premenopausal PatientsBackgroundClinicalTrials.gov
NCT00073073Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast CancerBackgroundClinicalTrials.gov
NCT00092950Exercise in Women at Risk for Breast CancerBackgroundClinicalTrials.gov
NCT00603967Effect of Aromatase Inhibitors on Bones and GenesBackgroundClinicalTrials.gov
NCT02394496Overcoming Endocrine Resistance in Metastatic Breast CancerBackgroundClinicalTrials.gov
NCT02936999Vitamin D Supplementation in Women With DCIS and/or LCISBackgroundClinicalTrials.gov
NCT03112031Treatment With Tamoxifen in Cryptococcal MeningitisBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections7

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in9923863Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study.https://conductscience.org/library/papers/9923863PubMed
Comment in10218518Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.https://conductscience.org/library/papers/10218518PubMed
Comment in10772691Re: tamoxifen prevention of breast cancer: an instance of the fingerpost.https://conductscience.org/library/papers/10772691PubMed
Comment in10793117Re: weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.https://conductscience.org/library/papers/10793117PubMed
Comment in10841836Re: Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors.https://conductscience.org/library/papers/10841836PubMed
Comment in11562395Re: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.https://conductscience.org/library/papers/11562395PubMed
Comment in21881041Do all patients with breast cancer require systemic adjuvant therapy?https://conductscience.org/library/papers/21881041PubMed

Download CSV of comments and corrections

Cited by1,172

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4,153 citations.

PMIDTitleJournalYearIn PapersSource
42868199Estradiol-associated extracellular signaling in the human breast in vivo identifies mast cells as tumor-supportive stromal mediators.Oncoimmunology2026https://conductscience.org/library/papers/42868199PubMed
42657161Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions.Front Oncol2026https://conductscience.org/library/papers/42657161PubMed
42593556Understanding patient perspectives on breast cancer risk: a qualitative study to inform genetic testing communication in the primary care setting.J Community Genet2026https://conductscience.org/library/papers/42593556PubMed
42499015Recent Advances in Genetic Testing and Clinical Management of Hereditary Breast and Ovarian Cancer (HBOC) in India.Cancer Med2026https://conductscience.org/library/papers/42499015PubMed
42482767Identification and management of genetic susceptibility to cancer: UK perspective.BMJ Oncol2026https://conductscience.org/library/papers/42482767PubMed
42232584Rebalancing immunity: The emerging role of selective estrogen receptor modulators in immunity and autoimmunity.Curr Trends Immunol2025https://conductscience.org/library/papers/42232584PubMed
42218536Compact breast parenchyma: imaging and transcriptomic correlates.J Transl Med2026https://conductscience.org/library/papers/42218536PubMed
42168229Women's preferences for breast cancer risk-reducing medications: a discrete choice experiment study.NPJ Breast Cancer2026https://conductscience.org/library/papers/42168229PubMed
41927957Reply to "Beyond Uptake Aligning Low-Dose Tamoxifen Adherence with Absolute Breast Cancer Risk," by Hu, Zhiping et al.Ann Surg Oncol2026https://conductscience.org/library/papers/41927957PubMed
41918186Clinical Outcomes of Lobular Carcinoma In Situ: Risk of Invasive Cancer Development.J Breast Cancer2026https://conductscience.org/library/papers/41918186PubMed
41684590Endocrine regimen and early subclinical atherosclerosis in premenopausal HR+/HER2- breast cancer: real-world evidence and regimen-dependent effects of Sanhuang Decoction.Front Oncol2026https://conductscience.org/library/papers/41684590PubMed
41681861Cancer Prevention Clinical Trials: Advances and Challenges.Cancers (Basel)2026https://conductscience.org/library/papers/41681861PubMed
41654661Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose Tamoxifen.Ann Surg Oncol2026https://conductscience.org/library/papers/41654661PubMed
41510186Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention.MedComm (2020)2026https://conductscience.org/library/papers/41510186PubMed
41468356Factors Associated with Low-Dose Tamoxifen Use among Women with Atypical Hyperplasia or Lobular or Ductal Carcinoma In Situ.Cancer Prev Res (Phila)2026https://conductscience.org/library/papers/41468356PubMed
41400398Tamoxifen inhibits histidine kinases of M. tuberculosis two-component signaling systems.Microbiol Spectr2026https://conductscience.org/library/papers/41400398PubMed
41379146Interventions to improve adherence to oral endocrine therapy for prevention or treatment of breast cancer in Black women of low socioeconomic status.Support Care Cancer2025https://conductscience.org/library/papers/41379146PubMed
41364346Overview of ocular toxicities associated with breast cancer therapies.Breast Cancer Res Treat2025https://conductscience.org/library/papers/41364346PubMed
41300964Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions.Cancers (Basel)2025https://conductscience.org/library/papers/41300964PubMed
41253392[Fertility management in breast cancer patients: current strategies and research advances].Zhejiang Da Xue Xue Bao Yi Xue Ban2025https://conductscience.org/library/papers/41253392PubMed

See all 1,172 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9747868

GET https://conductscience.org/api/papers/v1/9747868/cited_by?page=2